David Patrick Nixon
Chairman and CEODavid brings 23 years of healthcare experience and a record of entrepreneurial leadership to his role as CEO of InformedDNA. Since joining InformedDNA in 2007, David has led the company’s transformation from the premier national genetic counseling provider network to becoming the first mover in the rapidly growing field of genetic testing utilization management. InformedDNA is now the leading genetic benefits management organization; working with national and regional health plans as well as hospitals and health systems throughout the US to ensure patients have convenient access to genetic services and providers are able to work with genetic specialists for genetic testing decision support.
Dr. Bard Geesaman, MD, PhD
Director, Board of DirectorsDr. Bard Geesaman joined InformedDNA's board of directors following an investment in the company by MPM Capital Partners' SunStates Fund LP. Bard began working with MPM in 2001 as part of the management team for the portfolio company Elixir Pharmaceuticals. In 2006 he became a venture partner at MPM and co-founded Solasia, a specialty pharmaceutical company in Asia developing oncology products. Prior to working at MPM, Bard was a general partner at F2 Ventures, a U.K. based investment firm where he managed private investments. Bard received his Ph.D. in systems biology from MIT, his M.D. from Harvard Medical School, and his bachelor’s degree in neurobiology from the University of California, Berkeley. He is board certified in internal medicine and completed his residency at Massachusetts General Hospital.
R. David Kretschmer
Director, Board of DirectorsDavid is Senior Vice President, Treasurer and Chief Investment Officer of Anthem Inc. He is responsible for Anthem’s cash management, management of the company’s investment portfolios (including the $25 billion insurance reserve portfolio and $5 billion in retirement assets), capital management (including debt issuance, stock issuance and repurchase, and banking and rating agency relations), and risk management. He has been with Anthem, since 1991. David was previously Vice President of Portfolio Management for GW Sierra Trust Funds. Prior to that, he was responsible for the management of corporate cash and pension assets for Flying Tiger Inc. and manager of investment programs for the Times Mirror Company. He started his career with the Chrysler Corporation where he worked in corporate finance on capital structure and M&A. David received his M.B.A. from the University of Chicago with a specialization in finance and concentrations in statistics and accounting. He received his Bachelor of Science degree from George Washington University where he graduated magna cum laude with a major in economics. David serves on the boards of CF Group, an international furniture manufacturer, Trailer Bridge, an international shipping company, and LYNX, a not-for-profit which directs investments to minority owned businesses throughout Indiana.
Stephen M. Mengert
Director, Board of DirectorsStephen Mengert has been a senior financial executive in healthcare and finance for over 20 years, including 13 years as the chief financial officer of a public company. Stephen served as senior vice president of finance and chief financial officer of Medsolutions from 2006 to 2011. Before joining MedSolutions, he was the CFO for Matria Healthcare, a publicly traded disease management services company. Stephen earned a bachelor's and master’s degree in business administration with a specialty in finance from Georgia State University. He is a member of the Financial Executives Institute. In 2010, he was Tennessee’s finalist for CFO of the year.
John N. Nunnelly
Director, Board of DirectorsJohn Nunnelly is a retired group president from McKesson Corporation where he was responsible for a broad range of business units in the healthcare information technology industry. John is currently a member of the board of directors for National Research Corporation, a leading provider of performance measurement services for healthcare payer and provider organizations. He also serves as a director for Illuminate Health LLC, an NRCI affiliate. In addition, John is an adjunct professor in the College of Nursing at the University of Massachusetts. He serves on numerous community boards. John graduated from the United States Merchant Marine Academy, Kings Point, and earned his master’s degree in business administration from the University of Massachusetts, Isenberg School of Management.
Director, Board of DirectorsJason has extensive experience in healthcare, human resources, client relationship development and sales/product management. He is responsible for diversified business growth and execution strategies of non health insurance assets for Zaffre Investments, a wholly owned subsidiary of Blue Cross Blue Shield of Massachusetts. He also serves as chief strategy officer for the health plan. Previously, Jason was executive vice president for Health Dialog, responsible for market-facing activities, strategic business partnerships and acquisitions. Also, he was principal at Mercer Human Resource Consulting, vice president at Imagitas, and vice president and president at Ceridian Performance Partners. Jason holds a bachelor's degree in political science and serves on the board of directors and committees for several nonprofit organizations.
Rebecca Sutphen, MD, FACMG
President & Chief Medical OfficerDr. Rebecca Sutphen has broad clinical and molecular genetics expertise in conditions affecting both adults and children. She is among the few individuals certified by the American Board of Medical Genetics in clinical genetics, molecular genetics and cytogenetics. Rebecca previously served as director of Clinical Genetics for Moffitt Cancer Center & Research Institute. She is also an experienced researcher in genomics & proteomics and has been funded by the American Cancer Society, the Department of Defense and the National Institutes of Health. Rebecca has received numerous awards and honors, including being named to "Florida's Super Doctors," "America's Top Doctors for Cancer," and "Best Doctors in America," as well as the National Comprehensive Cancer Network Guidelines Panel, which sets the standard-of-care for genetics and familial cancer screening.